ABSTRACT
Fatality from coronavirus disease 19 (COVID-19) is a major problem globally and so identification of its underlying molecular mechanisms would be helpful. The combination of COVID-19 clinical data and genome sequence information is providing a potential route to such mechanisms. Here we took a candidate gene approach to UK Biobank data based on the suggested roles of endothelium and membrane proteins in COVID-19. We focussed on the PIEZO1 gene, which encodes a non-selective cation channel that mediates endothelial responses to blood flow. The analysis suggests 3 missense PIEZO1 single nucleotide polymorphisms (SNPs) associated with COVID-19 fatality independently of risk factors. All of them affect amino acids in the proximal N-terminus of PIEZO1, which is an unexplored region of the protein. By using molecular modelling we predict location of all 3 amino acids to a common outward-facing structure of unknown functional significance at the tips of the PIEZO1 propeller blades. Through genome sequence analysis we show that these SNPs vary in prevalence with ethnicity and that the most significant SNP (rs7184427) varies between 65 to 90% even though the reference amino acid is evolutionarily conserved. The data suggest PIEZO1 as a contributor to COVID-19 fatality and factor in ethnic susceptibility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported by a Wellcome Trust Investigator Award to DJB, a BHF Daphne Jackson Fellowship to VD and Leeds Cardiovascular Endowment funds for CWC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revised to account for updated UK Biobank data on this topic.
Data Availability
The data analysed are available to the registered users through UK Biobank
